Recently, the State Intellectual Property Office announced the awarding decision of the 25th China Patent Award. HEC Pharmaceutical's invention patent "Oseltamivir Phosphate Granules and Preparation Method thereof" (patent number ZL200610066995.7) won the 25th China Patent Gold Award.
The China Patent Award is jointly sponsored by the State Intellectual Property Office and the World Intellectual Property Organization. It has nine awards, including the China Patent Gold Award, the China Design Gold Award, and the China Patent Award Best Organization Award. Among them, the gold award project must have a significant level of innovation, outstanding market value and extensive social influence, representing the highest honor in China's intellectual property field. The award of the invention patent "Oseltamivir Phosphate Granules and Preparation Methods" of East Sunshine Pharmaceutical not only demonstrates the company's innovative strength in the pharmaceutical field, but also confirms the product's outstanding performance in terms of technological innovation, clinical value, and social influence.

Kewei® Granules, Protecting Children's Flu Health for 18 Years

Oseltamivir is recognized worldwide as the first choice for the prevention and treatment of influenza. It has been used clinically for more than 20 years. The original formulations include capsules, dry suspensions and dry syrups. The latter two formulations for children have defects such as inconvenience in use, dosage errors and easy contamination, and their usage rates are relatively low in countries around the world. In 2008, faced with the problem of no drugs available for children with influenza in China, the Beijing Academy of Military Medical Sciences led the world's first patented formulation of oseltamivir granules, which was then industrialized by East Sunshine Changjiang Pharmaceuticals under the trade name: Kewei®.

Although there is already production experience of oseltamivir capsules as a basis, granule preparations have higher requirements for uniformity and stability. With the core goal of improving product safety and stability, the R&D team has spent two years on technical research and finally made a breakthrough in the key process, allowing Kewei® granules to be successfully approved for marketing, filling the gap in China's children's special anti-influenza drugs.

The award-winning patented formulation of Kewei® granules is individually packaged at 15 mg/bag, and can be accurately dosed according to the child's weight or specific medical needs, such as 30 mg/time (2 bags) for children ≤15 kg, 45 mg/time (3 bags) for children 15-23 kg, 60 mg/time (4 bags) for children 23-40 kg, and 75 mg/time (5 bags) for children >40 kg. It is convenient and flexible to take by bag, and avoid errors in splitting tablets. The granule dosage form is easy to take. In addition to taking it with warm water, it can also be taken with food. The sweet taste is especially suitable for children. Major global authoritative organizations and clinical guidelines (such as the US CDC) recommend that oseltamivir can be used for children over 14 days old. Currently, East Sunshine Pharmaceutical, as a leading company in the field of influenza, owns 8 invention patents for the oseltamivir series, and has achieved an annual production capacity of 3.6 billion bags of Kewei® granules, fully guaranteeing the supply of antiviral drugs for children during the influenza season. In the 18 years since it was launched on the market, Kewei® Granules have successfully solved the problem of a lack of medicine for children with influenza, and have become a household name for the treatment of childhood influenza, protecting the health of hundreds of millions of children in China.

Patents build a foundation and establish a global innovation barrier

Patents are one of the core assets of pharmaceutical companies and are also the key to protecting innovative achievements and maintaining market competitive advantages. Since its establishment in 2003, HEC Pharmaceutical has always regarded patent strategy as the core support for innovation-driven global development. So far, HEC Pharmaceutical has built a strong intellectual property protection system worldwide: the total number of invention patents applied for has exceeded 2,400, and more than 1,400 invention patents have been authorized.

According to the Frost & Sullivan report, based on the number of patents published in China and the number of authorized patent announcements from January 1, 2014 to December 31, 2023, HEC Pharmaceutical ranks first among Chinese pharmaceutical companies; according to the joint release of IPRdaily Chinese website and incoPat Innovation Index Research Center, in the 2022 Global Biopharmaceutical Industry Invention Patent Ranking TOP 100, HEC Pharmaceutical's patent ranking ranks 44th in the world. These achievements indicate that HEC Pharmaceutical has built a three-dimensional intellectual property protection system of "domestic leadership and global competition", which has created a solid technical moat for the company's international pharmaceutical innovation and development. Innovation-driven, forging a diversified product matrix

Innovation as the source, development as the basis - this is the eternal corporate proposition of East Sunshine Pharmaceutical.

Established in 2005, HEC Pharmaceutical Research Institute has been continuously increasing its R&D investment with "innovation" and "internationalization" as its dual driving forces. At present, the company has formed a professional R&D team of more than 1,100 people, and has a national key laboratory for the research and development of new anti-infective drugs, a national intellectual property demonstration enterprise, and a postdoctoral research workstation. At the same time, in the wave of digital transformation, HEC Pharmaceutical has proactively launched an AI pharmaceutical platform, and has joined hands with Huawei, Beijing Sunway World, Deepin Technology, etc. to build an intelligent scientific research carrier, greatly improving the efficiency of molecular design and clinical trials, breaking through the bottleneck of traditional R&D, and significantly accelerating the transformation process of innovative drugs from laboratory to clinical application, and finally building a full-chain innovation system of "basic research-technology development-clinical transformation". Relying on this system, HEC Pharmaceutical has built a product pipeline covering multiple key areas such as infection, chronic diseases, and tumors, and has approved 150 drugs worldwide, more than 100 drugs under development, including nearly 50 Class I innovative drugs, 3 new drugs have been launched, 1 new drug has applied for listing, and 10 new drugs are in clinical phase II and III.
Leading with innovation and fulfilling our commitment to global health.

https://news.yaozh.com/archive/45629.html